Metastatic cancers
Drug research and approvals for metastatic cancers: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 3,265 studies of metastatic cancers are recruiting on ClinicalTrials.gov, and Health Canada has authorized 7 drug trials for it since 2013.
- Recruiting worldwide: 3,265
- Trials authorized in Canada: 7
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 3,265 recruiting on ClinicalTrials.gov ↗- Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced…NCT07619521 · Phase 1 / Phase 2 · National Cancer Institute (NCI) · starts Jun 1, 2027
- Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at DiagnosisNCT07578116 · Phase 3 · SWOG Cancer Research Network · starts Mar 9, 2027
- Intraoperative Neuromonitoring of Sacral Reflexes to Predict Post Operative Function in Patients Undergoing Sacrectomy…NCT07707024 · Not applicable · City of Hope Medical Center · starts Jan 10, 2027
- Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or…NCT07271355 · Phase 3 · City of Hope Medical Center · starts Jan 4, 2027
- Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)NCT07845786 · Phase 2 · Exelixis · starts Dec 15, 2026
- A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung CancerNCT07603856 · Phase 2 · University of Chicago · starts Dec 12, 2026
- A Navigation Program to Improve Survivorship Support Service Participation Among Non-metastatic Breast Cancer SurvivorsNCT07699991 · Not applicable · Ohio State University Comprehensive Cancer Center · starts Dec 9, 2026
- ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and RadiationNCT07015853 · Phase 2 · Stephen Shiao · starts Dec 1, 2026
- ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic…NCT07444541 · Phase 1 / Phase 2 · Anova Innovation Limited · starts Dec 1, 2026
- SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-METNCT07873450 · Phase 1 / Phase 2 · Full-Life Technologies UK Limited · starts Dec 1, 2026
Trials Authorized in Canada
Newest first; search them all in Canada trials| Sep 25, 2025 | A phase 1/2, multicenter, open label, dose escalation & dose expansion study of jk06, a 5t4 antibody drug conjugate, in patients with unresectable locally…JK06 | SALUBRIS BIOTHERAPEUTICS, INC. | Ongoing |
| Aug 4, 2023 | A phase 1/2, first-in-human, open-label, dose-escalation study of tak-280 in patients with unresectable locally advanced or metastatic cancerTAK-280 | Takeda Pharmaceuticals USA | Closed |
| Oct 20, 2022 | A randomized, open-label, multicenter phase 3 trial of domvanalimab, zimberelimab, and chemotherapy versus nivolumab and chemotherapy in participants with…ZIMBERELIMAB (AB122) / DOMVANALIMAB (AB154) / OXALIPLATIN / LEUCOVORIN /… | ARCUS BIOSCIENCES, INC. | Closed |
| Feb 24, 2021 | In vivo lung perfusion (ivlp) as an adjuvant treatment for patients with resectable or unresectable pulmonary metastases of colorectal carcinomasOXALIPLATIN | UNIVERSITY HEALTH NETWORK | Ongoing |
| Jan 14, 2020 | A phase 1/2a two-part, open-label, multicenter study to evaluate the safety and pharmacokinetics of oc-001 as monotherapy and in combination with an anti-pd-l1…OC-001 | OCELLARIS PHARMA, INC. | Ongoing |
| Mar 13, 2019 | Phase 1 study of zw49 in patients with locally advanced (unresectable) or metastatic her2-expressing cancersZW49 INJECTION | ZYMEWORKS BC INC. | Ongoing |
| Feb 16, 2018 | Phase 1 trial of zw25 in patients with locally advanced (unresectable) and/or metastatic her2-expressing cancersZW25 | Jazz Pharmaceuticals | Ongoing |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA